DIAKOVERE Krankenhaus gGmbH — Clinical Trial Site

13 Registered trials

4 Currently recruiting

Organisation

DIAKOVERE Krankenhaus gGmbH

Location

Hanover, Germany

Identifier

ORG-100024065

Address

Schwemannstrasse 17-19, Kirchrode, 30559, Germany

Departments

Frauenklinik
Gynäkologie
Henriettenstift Frauenklinik
Klinik für Gynäkologische Chirurgie Senologie und Onkologie
Klinik für Neurologie und Neurophysiologie
MediProjekt

Clinical trials at this site (13)

Search interface

Usnoflast Neuromuscular Investigation for Treatment Efficacy in ALS (UNITE-ALS) Pending

2025-522580-15-00 Amyotrophic Lateral Sclerosis (ALS) 4
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (PREVAiLS) Recruiting

2025-524002-16-00 Amyotrophic Lateral Sclerosis 5 2026-05-12
A clinical trial to learn about the effects of VHB937 in people with amyotrophic lateral sclerosis (ALS) Recruiting

2024-512536-29-00 Amyotrophic Lateral Sclerosis (ALS) 4 2025-02-28
A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in… Recruiting

2022-501152-28-00 Breast Cancer 4 2022-12-21
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended

2024-513540-29-00 Breast Cancer 5 2024-11-07
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended

2023-505928-59-00 Triple Negative or Hormone Receptor low/HER2-negative B 5 2024-04-15
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk… Ended

2024-515769-32-00 HR+/HER2- early breast cancer 5 2019-07-02
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13
Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Canc… Ended

2024-513167-68-00 endometrial cancer 5 2017-11-29
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15